ArticleCell and tissue banking2025
Effects of super-activated platelet lysate and bone mesenchymal stem cells on bone regeneration, and expression of bone metabolism-related factors in rats.
Article in Cell and tissue banking, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The present study aimed to evaluate the effectiveness of super-activated platelet lysate (sPL), as well as sPL in combination with bone marrow mesenchymal stem cells (BMSCs) in treating bone defects in rats. Ninety rats with induced radial defects were divided into three groups: sPL/BMSCs, sPL, and control. The healing process was evaluated using X-rays, Lane Sandhu scores, HE staining, RT-qPCR, immunohistochemistry, and ELISA. Both sPL and sPL/BMSCs facilitate bone repair. Compared to the other groups, the sPL/BMSCs group showed higher OCN, OSX, and RUNX2 gene expression until 10 weeks after treatment ALP levels in the sPL group increased until week 6 and remained elevated until week 10, with the sPL/BMSCs group showing significantly higher peak ALP levels. IGF-1, TGF-β, and VEGF levels in both treatment groups were higher than in the control group. Our study demonstrated that both sPL and sPL/BMSC transplants at the bone defect site can promote bone healing and modulate bone metabolism-related factors. However, the effect of sPL/BMSCs was superior to sPL alone.
Indexed as
Identifiers
41045387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.